Strategies to enhance immune cell activation & cancer cell killing
Immuno-Oncology Insights 2022; 3(11), 553–559
Published: 15 December 2022
Abigail Pinchbeck, Assistant Editor, BioInsights, speaks to Karine Breckpot, Director, Laboratory for Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel
Technologies such as mRNA, lentiviral vectors, and nanobodies are vital tools in the immuno-oncology arsenal. In this article, Karine Breckpot, the director of the Laboratory for Molecular and Cellular Therapy (LMCT), explains how she applies the latest technology to her work in engineering dendritic cells for immune activation and T cells for cancer cell rejection – and her predictions for 2023 and beyond.